Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017

被引：15
|
作者：
Frank I. Scott
Gary R. Lichtenstein
机构：
[1] University of Colorado Anschutz Medical Campus,Crohn’s and Colitis Center, Division of Gastroenterology and Hepatology
[2] Perelman School of Medicine,Gastroenterology Division
[3] University of Pennsylvania,undefined
来源：
Current Treatment Options in Gastroenterology | 2018年 / 16卷 / 1期
关键词：
Biosimilars; Indication extrapolation; Interchangeability; Infliximab; Adalimumab; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis;
D O I：
10.1007/s11938-018-0177-z
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：147 / 164
页数：17
相关论文
共 50 条
  • [21] Biosimilars in inflammatory bowel disease
    Siegmund, B.
    Atreya, R.
    Bokemeyer, B.
    Kruis, W.
    Mudter, J.
    Sander, C.
    Schreiber, S.
    Reindl, W.
    Zeissig, S.
    Kucharzik, T.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2016, 54 (11): : 1217 - 1222
  • [22] Biosimilars in inflammatory bowel disease
    Talathi, Saurabh
    Baig, Kondal R. Kyanam Kabir
    JOURNAL OF DIGESTIVE DISEASES, 2020, 21 (11) : 610 - 620
  • [23] Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
    Al Sulais, Eman
    AlAmeel, Turki
    BIOLOGICS-TARGETS & THERAPY, 2020, 14 : 1 - 11
  • [24] Biosimilars in the therapy of inflammatory bowel diseases
    Hlavaty, Tibor
    Letkovsky, Juraj
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 26 (06) : 581 - 587
  • [25] Anti-TNFα in inflammatory bowel disease: from originators to biosimilars
    Zeng, Zhen
    Lin, Hao
    Jiang, Mingshan
    Yuan, Jing
    Li, Xi
    Jia, Yongbin
    Yang, Li
    Zhang, Hu
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [26] Benefits of Biosimilars in the Management of Patients with Inflammatory Bowel Disease: An International Survey
    D'Amico, Ferdinando
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (11)
  • [27] Biosimilars in Inflammatory Bowel Disease (IBD): Experiences and perceptions of german gastroenterologists
    Bokemeyer, Bernd
    Dignass, Axel
    Schreiber, Stefan
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2017, 55 (04): : 369 - 374
  • [28] Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
    Ben-Horin, Shomron
    Vande Casteele, Niels
    Schreiber, Stefan
    Lakatos, Peter Laszlo
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (12) : 1685 - 1696
  • [29] The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease
    Severs, M.
    Oldenburg, B.
    van Bodegraven, A. A.
    Siersema, P. D.
    Mangen, M-J. J.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 (03) : 289 - 296
  • [30] Preliminary Evidence Supporting a Framework of Psychological Adjustment to Inflammatory Bowel Disease
    Kiebles, Jennifer L.
    Doerfler, Bethany
    Keefer, Laurie
    INFLAMMATORY BOWEL DISEASES, 2010, 16 (10) : 1685 - 1695
12345